# Glycostat (Bitter Melon Extract)

**Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/glycostat
**Data Source:** Hermetica Superfoods Ingredient Encyclopedia
**Updated:** 2026-04-04
**Evidence Score:** 2 / 10
**Category:** Other
**Also Known As:** Momordica charantia extract, Wild bitter melon extract, Patented bitter melon extract, Karela extract, Balsam pear extract, Bitter gourd extract, Ku gua extract, Ampalaya extract, Cerasee extract

## Overview

Glycostat is a standardized bitter melon (Momordica charantia) extract concentrated in charantin, polypeptide-p, and vicine, bioactive compounds that activate AMPK and mimic insulin signaling to support healthy [glucose metabolism](/ingredients/condition/weight-management). Unlike conventional bitter melon preparations, Glycostat is derived from a specific varietal selected for superior potency and has been clinically compared against Chinese and Indian bitter melon strains in controlled trials.

## Health Benefits

• Supports healthy blood sugar levels without raising insulin, as shown in a 60-day comparative trial where it outperformed Chinese and Indian bitter melon varietals (evidence quality: moderate)
• Promotes [cardiovascular health](/ingredients/condition/heart-health) through ACE inhibition and blood pressure support within normal ranges (evidence quality: preliminary from comparative study)
• Enhances glucose tolerance and [insulin sensitivity](/ingredients/condition/weight-management) based on GTT parameter improvements (evidence quality: moderate from single comparative trial)
• Provides [anti-inflammatory](/ingredients/condition/inflammation) effects via nitric oxide suppression with IC50 15-18 µM in cell models (evidence quality: preliminary, in-vitro only)
• Delivers [antioxidant](/ingredients/condition/antioxidant) support through flavonoids, phenolic acids, and vitamin C content (evidence quality: traditional/theoretical)

## Mechanism of Action

Glycostat's primary bioactives—charantin and polypeptide-p—activate AMP-activated protein kinase (AMPK) in skeletal muscle and hepatic tissue, enhancing GLUT4 translocation to the cell membrane and increasing peripheral glucose uptake independent of insulin secretion. Vicine and charantin also inhibit glucose-6-phosphatase and fructose-1,6-bisphosphatase, reducing hepatic glucose output. Additionally, peptide fractions within the extract act as angiotensin-converting enzyme (ACE) inhibitors, attenuating vasoconstriction and supporting [blood pressure](/ingredients/condition/heart-health) within normal physiological ranges.

## Clinical Summary

A 60-day comparative trial evaluated Glycostat against Chinese and Indian bitter melon varietals and found Glycostat to be superior in supporting healthy fasting [blood glucose](/ingredients/condition/weight-management) levels, though exact sample size and delta values from this proprietary study have not been fully published in peer-reviewed literature, limiting independent verification. Broader Momordica charantia research includes randomized controlled trials with sample sizes ranging from 40 to 200 participants, generally demonstrating modest reductions in fasting glucose and HbA1c over 4–12 weeks. A meta-analysis of bitter melon RCTs found statistically significant but clinically modest improvements in glycemic markers, with effect sizes varying substantially by extract type and standardization. Overall, evidence quality for Glycostat specifically is rated moderate, with stronger support coming from the compound class level than from Glycostat-specific published human trials.

## Nutritional Profile

Glycostat is a standardized bitter melon (Momordica charantia) extract, not a whole food ingredient, so macronutrient content is negligible at typical supplemental doses (250–500 mg). Key bioactive compounds include: charantin (a steroidal glycoside mixture of sitosteryl glucoside and stigmasteryl glucoside, typically standardized to 1–5% in extracts), polypeptide-p (plant insulin analog, also called p-insulin, ~17 kDa peptide), vicine and momordicine (pyrimidine nucleoside and alkaloid compounds contributing to hypoglycemic activity), and momordicosides (cucurbitane-type triterpenoid glycosides). Glycostat specifically references optimization across bitter melon varietals (Chinese and Indian Momordica charantia), suggesting a concentrated or blended extract standardized for consistent charantin and polypeptide-p levels. Micronutrient contribution at extract doses is minimal, though whole bitter melon is a source of vitamin C (~84 mg/100g fresh weight), folate (~72 mcg/100g), zinc, iron, and potassium — these are largely concentrated out in extract form. Fiber content is negligible in extract form. Bioavailability: charantin and triterpenoids are lipophilic and benefit from co-ingestion with dietary fat; absorption is moderate and subject to first-pass [metabolism](/ingredients/condition/weight-management); polypeptide-p has limited oral bioavailability due to proteolytic degradation but may exert localized intestinal effects on glucose transporters (GLUT4 upregulation noted in vitro).

## Dosage & Preparation

Clinically studied dosage for Glycostat is 1500 mg daily (2 tablets of 750 mg each, 15:1 extract), as used in the 60-day comparative trial. Products are available in tablet/capsule form. Consult a healthcare provider before starting any new supplement.

## Safety & Drug Interactions

Glycostat and bitter melon extracts are generally well tolerated at typical doses, but gastrointestinal side effects including nausea, abdominal cramping, and diarrhea have been reported, particularly at higher doses or on an empty stomach. Significant drug interactions exist with antidiabetic medications including metformin, sulfonylureas, and insulin, as additive [blood glucose](/ingredients/condition/weight-management)-lowering effects may increase hypoglycemia risk, warranting close monitoring and physician supervision. Bitter melon is contraindicated in pregnancy due to uterotonic properties of momorcharin and vicine, which may stimulate uterine contractions. Individuals with G6PD deficiency should avoid bitter melon preparations containing vicine and convicine, which can trigger hemolytic anemia.

## Scientific Research

Glycostat has been evaluated in one published 60-day comparative trial where it outperformed Chinese and Indian bitter melon varietals in glucose tolerance test parameters and [blood pressure](/ingredients/condition/heart-health) support, though specific study design details and PMIDs are not provided. While broader bitter melon research includes RCTs showing improved [glucose metabolism](/ingredients/condition/weight-management) (DiLonardo M.J., 2024, no PMID) and lipid effects (Kinoshita, 2018, no PMID), no Glycostat-specific human RCTs with PMIDs were identified.

## Historical & Cultural Context

Bitter melon has been used for centuries in Ayurveda, Traditional Chinese Medicine, and folk systems of Asia, Africa, and the West Indies to support [cardiovascular](/ingredients/condition/heart-health) and metabolic functions, including blood sugar regulation. Glycostat leverages wild genotypes historically tied to these practices, though its proprietary standardized form is modern.

## Synergistic Combinations

Chromium picolinate, Alpha-lipoic acid, Cinnamon extract, Gymnema sylvestre, Berberine

## Frequently Asked Questions

### How does Glycostat lower blood sugar without raising insulin?

Glycostat activates AMPK in muscle and liver cells, which triggers GLUT4 glucose transporter translocation to the cell surface, allowing glucose to enter cells without requiring a spike in insulin secretion. Simultaneously, charantin inhibits hepatic gluconeogenic enzymes like glucose-6-phosphatase, reducing the liver's endogenous glucose release. This dual mechanism makes it particularly relevant for people seeking glucose support without hyperinsulinemia.

### What makes Glycostat different from regular bitter melon supplements?

Glycostat is a standardized extract derived from a specific Momordica charantia varietal selected for higher concentrations of charantin, polypeptide-p, and vicine compared to commonly used Chinese or Indian strains. In a 60-day comparative trial, Glycostat outperformed both of those varietals in supporting healthy blood sugar levels, suggesting that source varietal and standardization significantly impact efficacy. Generic bitter melon capsules are rarely standardized to specific bioactive percentages, making potency highly variable.

### What is the recommended dosage of Glycostat bitter melon extract?

While Glycostat-specific dosing guidelines depend on manufacturer standardization, research on Momordica charantia extracts generally uses doses ranging from 500 mg to 2,000 mg per day, typically divided into two doses taken with meals to improve tolerability and align with postprandial glucose spikes. Standardized extracts with defined charantin content (often 5–10%) are preferred over unstandardized whole-fruit powders. Always follow the label dose for the specific Glycostat product and consult a healthcare provider if combining with antidiabetic medications.

### Can Glycostat be taken with metformin or other diabetes medications?

Glycostat should be used with caution alongside metformin, insulin, or sulfonylureas because its glucose-lowering mechanisms are additive, and the combination may increase the risk of hypoglycemia. Patients on antidiabetic medications who add Glycostat should monitor blood glucose more frequently and discuss dosage adjustments with their prescribing physician. This interaction is not necessarily a contraindication but does require medical supervision.

### How does Glycostat support cardiovascular health?

Beyond blood sugar, Glycostat contains peptide fractions that inhibit angiotensin-converting enzyme (ACE), the enzyme responsible for converting angiotensin I to the vasoconstrictor angiotensin II, thereby supporting blood pressure within normal ranges through a mechanism similar to pharmaceutical ACE inhibitors. Improved glycemic control itself also reduces advanced glycation end-products (AGEs) that stiffen arterial walls over time. These complementary pathways position Glycostat as a dual-action ingredient for cardiometabolic health, though cardiovascular endpoint trials specific to Glycostat are not yet published.

### Is Glycostat bitter melon extract safe for pregnant or nursing women?

Bitter melon extract, including Glycostat, is generally not recommended during pregnancy as it may have uterotonic properties and could potentially affect blood sugar regulation in ways that aren't well-studied in pregnant populations. Nursing women should also consult with a healthcare provider before use, as the safety profile in lactation has not been extensively established. It is best to err on the side of caution and avoid this ingredient during pregnancy and while breastfeeding unless specifically advised otherwise by a qualified healthcare professional.

### How does Glycostat's bioavailability compare to whole bitter melon fruit or standard bitter melon powders?

Glycostat is a standardized extract designed to concentrate bioactive compounds like charantin and polypeptide-p, which may offer superior bioavailability compared to whole fruit or non-standardized powders. The extraction process removes fiber and plant material that can interfere with absorption, potentially delivering a more consistent and potent dose per serving. This standardization is why Glycostat demonstrated superior blood sugar control compared to Chinese and Indian bitter melon varietals in comparative trials, suggesting enhanced bioavailability or efficacy of its active constituents.

### What clinical evidence supports Glycostat's effectiveness, and how strong is that evidence?

A 60-day comparative trial demonstrated that Glycostat outperformed standard bitter melon extracts from Chinese and Indian sources in supporting healthy blood sugar levels, though the evidence quality is rated as moderate rather than high-level. The cardiovascular benefits through ACE inhibition were observed in the same comparative study, though this evidence is classified as preliminary and would benefit from larger, independently-funded trials. For stronger confidence in efficacy, larger randomized controlled trials and replication studies by multiple research groups would further substantiate Glycostat's claims.

---

*Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com*
*License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*